

Icepharma A/S

Sluseholmen 8A
2450 København SV

CVR no. 36 39 34 59

Annual report 2019

The annual report was presented and approved at the
Company's annual general meeting on

16 July 2020

Kristján Johannsson
chairman

Contents

Statement by the Board of Directors and the Executive Board	2
Independent auditor's report	3
Management's review	5
Company details	5
Operating review	6
Financial statements 1 January – 31 December	7
Income statement	7
Balance sheet	8
Statement of changes in equity	10
Notes	11

Statement by the Board of Directors and the Executive Board

The Board of Directors and the Executive Board have today discussed and approved the annual report of Icepharma A/S for the financial year 1 January – 31 December 2019.

The annual report has been prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 December 2019 and of the results of the Company's operations for the financial year 1 January – 31 December 2019.

Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.

We recommend that the annual report be approved at the annual general meeting.

Copenhagen, 16 July 2020
Executive Board:

Hörður Þórhallsson

Board of Directors:

Kristján Johannsson
Chairman

Jóhann Ingi Kristjánsson

Petrea Ingileif
Gudmundsdottir

Independent auditor's report

To the shareholder of Icepharma A/S

Opinion

We have audited the financial statements of Icepharma A/S for the financial year 1 January – 31 December 2019 comprising income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 December 2019 and of the results of the Company's operations for the financial year 1 January – 31 December 2019 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report.

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's responsibility for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control that Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements in Denmark will always detect a material misstatement when it exists. Misstatements may arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users made on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also

- identify and assess the risks of material misstatement of the company financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may

Independent auditor's report

involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.

- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the Management's review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the Management's review.

Copenhagen, 16 July 2020

KPMG

Statsautoriseret Revisionspartnerselskab
CVR no. 25 57 81 98

Kenn W. Hansen
State Authorised
Public Accountant
mne30154

Icepharma A/S
Annual report 2019
CVR no. 36 39 34 59

Management's review

Company details

Icepharma A/S
Sluseholmen 8A
2450 København SV

Telephone:	40544575
CVR no.:	36 39 34 59
Established:	30 September 2014
Registered office:	Copenhagen
Financial year:	1 January – 31 December

Board of Directors

Kristján Johannsson, Chairman
Jóhann Ingi Kristjánsson
Petrea Ingileif Gudmundsdottir

Executive Board

Hörður Þórhallsson

Auditor

KPMG
Statsautoriseret Revisionspartnerselskab
Dampfærgevej 28
DK-2100 Copenhagen

Management's review

Operating review

Principal activities

The primary activity is sale of pharmaceutical products and services.

Development in activities and financial position

The Company realised as expected a loss in 2019 as the Company is still in a start up phase. In 2019, the loss after tax was DKK 7,690 thousand compared to a loss of DKK 7,235 thousand in the year before.

The Company is financed by other group companies.

After the loss for the year of DKK 7,690 thousand and receipt of a grant from the shareholder of DKK 7,442 thousand, the equity at 31 December 2019 amounts to DKK 581 thousand.

The Company has obtained a letter of support from the parent company which, in the opinion of the Executive Board and the Board of Directors will be sufficient to secure sufficient financing of the activities for the next 12 months.

The financial statements for 2019 have therefore been prepared on the basis of going concern.

Events after the balance sheet date

We have not met any subsequent event after balance sheet date which affects the financial statement.

The Corona situation will not affect the financial statements for 2019. We are not aware of the future or how the Corona situation will affect the Company in 2020.

Financial statements 1 January – 31 December

Income statement

DKK	Note	2019	2018
Gross loss		-3,925,725	-3,628,386
Staff costs	2	-3,762,008	-3,439,122
Operating loss		-7,687,733	-7,067,508
Financial income		0	408
Financial expenses		-2,308	-6,967
Loss before tax		-7,690,041	-7,074,067
Tax on loss for the year	3	0	-161,074
Loss for the year		-7,690,041	-7,235,141
Proposed distribution of loss			
Retained earnings		-7,690,041	-7,235,141

Financial statements 1 January – 31 December

Balance sheet

DKK	Note	2019	2018
ASSETS			
Current assets			
Inventories			
Finished goods and goods for resale		723,705	1,362,260
Receivables			
Trade receivables		709,471	208,120
Other receivables		141,985	398,254
		851,456	606,374
Cash at bank and in hand		175,864	144,637
Total current assets		1,751,025	2,113,271
TOTAL ASSETS		1,751,025	2,113,271

Financial statements 1 January – 31 December

Balance sheet

DKK	Note	2019	2018
EQUITY AND LIABILITIES			
Equity			
Contributed capital		500,000	500,000
Retained earnings		80,815	328,645
Total equity		580,815	828,645
Liabilities			
Non-current liabilities			
Other payables		135,399	0
Current liabilities			
Trade payables		427,589	147,147
Payables to group entities		134,747	114,918
Corporation tax		0	161,074
Other payables		472,475	861,487
		1,034,811	1,284,626
Total liabilities		1,170,210	1,284,626
TOTAL EQUITY AND LIABILITIES		1,751,025	2,113,271
 Disclosure regarding going concern			
	4		
Contractual obligations, contingencies, etc.	5		
Related party disclosures	6		

Financial statements 1 January – 31 December

Statement of changes in equity

DKK	Contributed capital	Retained earnings	Total
Equity at 1 January 2019	500,000	328,645	828,645
Grants from parent company	0	7,442,211	7,442,211
Transferred over the distribution of loss	0	-7,690,041	-7,690,041
Equity at 31 December 2019	500,000	80,815	580,815

Financial statements 1 January – 31 December

Notes

1 Accounting policies

The annual report of Icepharma A/S for 2019 has been prepared in accordance with the provisions applying to reporting class B entities under the Danish Financial Statements Act with opt-in from higher reporting classes.

The accounting policies used in the preparation of the financial statements are consistent with those of last year.

Foreign currency translation

On initial recognition, transactions denominated in foreign currencies are translated at the exchange rates at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses.

Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rates at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the latest financial statements is recognised in the income statement as financial income or financial expenses.

Income statement

Gross profit

Pursuant to Section 32 of the Danish Financial Statements Act, the Company has decided only to disclose gross profit.

Revenue

Income from the sale of goods and services, is recognised in the income statement provided that delivery and transfer of risk to the buyer have taken place, the income may be reliably measured and is expected to be received.

Revenue is measured at fair value of the agreed remuneration excluding VAT and taxes charged on behalf of third parties. All forms of discounts granted are deducted from revenue.

To the extent that customers have the right to return goods received, revenue is recognised based on the Company's past record with returns. If the Company does not have a past record with similar transactions, revenue is recognised upon expiry of the period for returning the goods.

Cost of sales

Cost of sales comprises costs incurred to generate revenue for the year. This item also comprises direct costs for goods for resale and changes to inventory of goods for resale.

Financial statements 1 January – 31 December

Notes

1 Accounting policies (continued)

Other external costs

Other external costs include expenses related to distribution, sale, advertising, administration, premises, bad debts, payments under operating leases, etc.

Other external costs also comprise research and development costs that do not qualify for capitalisation.

Staff costs

Staff costs comprise salaries and wages, including holiday allowance, pension and other social security costs, etc., to the Company's employees excluding refunds from public authorities.

Financial income and expenses

Financial income and expenses are recognised in the income statement at the amounts relating to the financial year. Financial items comprise interest income and interest expense, as well as realised and unrealised gains and losses on receivables, payables and transactions in foreign currencies as well as surcharges and refunds under the on-account tax scheme, etc.

Tax on profit/loss for the year

Tax for the year comprises current tax and changes in deferred tax, including changes in tax rates. The tax expense relating to the profit/loss for the year is recognised in the income statement at the amount attributable to the profit/loss for the year and directly in equity at the amount attributable to entries directly in equity.

Balance sheet

Inventories

Inventories are measured at cost in accordance with the FIFO method. Inventories are written down to the lower of net realisable value and cost.

Goods for resale and consumables are measured at cost, comprising purchase price plus delivery costs.

The net realisable value of inventories is calculated as the sales amount less costs of completion and costs necessary to make the sale and is determined taking into account marketability, obsolescence and development in expected selling price.

Receivables

Receivables are measured at amortised cost, which corresponds to nominal value. The value is reduced by write-down for bad debts.

Cash at bank and in hand

Cash at bank and in hand comprise cash.

Financial statements 1 January – 31 December

Notes

1 Accounting policies (continued)

Corporation tax and deferred tax

Current tax payable and receivable is recognised on the balance sheet as tax computed on the taxable income for the year, adjusted for tax on the taxable income of prior years and for tax paid on account.

Deferred tax is measured using the balance sheet liability method on all temporary differences between the carrying amount and the tax value of assets and liabilities measured on the planned use of the asset or settlement of the liability.

Deferred tax assets, including the tax value of tax loss carryforwards, are recognised at the expected value of their utilisation within the foreseeable future; either as a set-off against tax on future income or as a set-off against deferred tax liabilities. Deferred net assets are measured at net realisable value.

Deferred tax is measured in accordance with the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. The change in deferred tax as a result of changes in tax rates is recognised in the income statement and in equity.

Liabilities

Financial liabilities are measured at amortized cost normally equal to net realisable value.

Financial statements 1 January – 31 December

Notes

DKK	2019	2018
2 Staff costs		
Wages and salaries	3,435,572	3,121,929
Pensions	314,129	303,062
Other social security costs	12,307	14,131
	<u>3,762,008</u>	<u>3,439,122</u>
Average number of full-time employees	<u>5</u>	<u>5</u>
3 Tax on profit/loss for the year		
The Company has a deferred tax asset of DKK 50 thousand at 31 December 2019. The tax asset is not recognised in the financial statements as it is unsure whether the assets can be utilized.		
Actual tax	<u>0</u>	<u>161,074</u>
	<u>0</u>	<u>161,074</u>
4 Disclosure regarding going concern		
The Company is financed by financial support from the parent company.		
After the loss for the year of DKK 7,690 thousand and receipt of a grant from the shareholder of DKK 7,442 thousand, the equity amounts to DKK 581 thousand.		
The Company has obtained a letter of support from the parent company which in the opinion of the Executive Board and the Board of Directors, will be sufficient to secure sufficient financing of the activities for the next 12 months.		
The financial statements for 2019 have therefore been prepared on the basis of going concern.		
5 Contractual obligations, contingencies, etc.		
Remaining operating lease obligations at the balance sheet date fall due at DKK 47 thousand within 1 year (2018: DKK 47 thousand).		
6 Related party disclosures		
Control		
Icepharma hf, Lynghalsi 13, 110 Reykjavik, Iceland.		
Icepharma hf holds the majority of the contributed capital in the Company.		
Icepharma A/S is part of the consolidated financial statements of Icepharma hf, which is the smallest group, in which the Company is included as a subsidiary.		
The consolidated financial statements of Icepharma hf can be obtained by contacting the companies at the addresses above.		

Financial statements 1 January – 31 December

Notes

Ownership

The following shareholders are registered in the Company's register of shareholders as holding a minimum of 5% of the votes or a minimum of 5% of the contributed capital:

Eignarhaldsfélagið Lyng ehf, Iceland.